Clinical Trial Update: Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the impact of inhaled fluticasone and salmeterol on airway dendritic cells in smokers. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone (fluticasone propionate)
• Salmeterol (salmeterol)

Snippet

Sponsor: University of Rostock | Conditions: Smoke-related Lung Diseases, Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED